R788
As of the edition of 20 October 2026, R788 is a drug known only by a code name: in active development; acts on SYK.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2019
- Kind
- Code name only
- Registered trials
- 2, 0 stopped early
- Disease areas
- Immune system; Blood and lymph; Bones, joints and muscles; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of R788.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SYK | Tyrosine-protein kinase SYK | P43405 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 2 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Rigel Pharmaceuticals | Lead sponsor of trials | 2006 to now |
| Kissei Pharmaceutical | Lead sponsor of trials | 2019 to now |